The treatment of myelodysplastic syndromes (MDS) involves improving patient survival and quality of life (QoL) and decreasing the likelihood of progression to AML. Although the treatment outcomes of MDS remain unsatisfactory, few comparative studies have been performed while comparing the outcomes of low-risk and intermediate-risk patients treated with supportive care and chemotherapeutics to those of patients treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, we designed a clinical control study to compare the outcomes of supportive care and chemotherapeutics versus allo-HSCT treatment in MDS patients. A total of 182 patients with MDS were enrolled in the study, including 91 in the no-HSCT (control) group and 91 in the allo-HSCT group. The complete remission (CR) rate in the allo-HSCT group was significantly higher than that in the control group (53.8% vs. 33.0%; P < 0.05). The QoL of patients in the HSCT group was much higher than that in the control group (53.8% vs. 37.4%; P < 0.05). The overall survival (OS) rates were 79.0% and 56.0% (P < 0.05) in the HSCT group and the control group, respectively. In conclusion, a high-dose fludarabine (Flu), busulfan (Bu), cyclophosphamide (CTX)-based conditioning regimen was well tolerated and significantly speeded hematopoietic recovery. In addition, this regimen increased procedure-related toxicity and improved QoL and OS.
Get full access to this article
View all access options for this article.
References
1.
ScottBL, SandmaierBM, StorerB, MarisMB, SorrorML, MaloneyDG, ChaunceyTR, StorbR and DeegHJ. (2006). Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia, 20:128–135.
2.
GreenbergPL. (2000). Myelodsyplastic syndrome. In: Hematology: Basic Principles and Practice. HoffmanR, BenzEJ, ShattilSJ, FurieB, CohenHJ, SilbersteinLE and McGlaveP, eds. Churchill Livingstone, New York, p. 1106.
3.
SanzGF, SanzMA, VallespiT, CañizoMC, TorrabadellaM, GarcíaS, IrriguibleD and San MiguelJF. (1989). Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood, 74:395–408.
4.
SilvermanLR, McKenzieDR, PetersonBL, HollandJF, BackstromJT, BeachCL and LarsonRA. (2006). Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol, 24:3895–3903.
5.
KantarjianH, OkiY, Garcia-ManeroG, HuangXL, BrienS, CortesJ, FaderlS, Bueso-RamosC, RavandiF, et al. (2007). Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronicmyelomonocytic leukemia. Blood, 109:52–57.
6.
SteensmaDP, BaerMR, SlackJL, BucksteinR, GodleyLA, Garcia ManeroG, AlbitarM, LarsenJS, AroraS, CullenMT and KantarjianH. (2009). Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol, 27:3842–3848.
7.
MelchertM and AList. (2008). Targeted therapies in myelodysplastic syndrome. Semin Hematol, 45:31–38.
8.
KimDY, LeeJH, ParkYH, LeeJH, KimSD, ChoiY, LeeSB, LeeKH, AhnSY, et al. (2012). Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplantation, 47:374–379.
9.
CutlerCS, LeeSJ, GreenbergP, DeegHJ, PérezWS, AnasettiC, BolwellBJ, CairoMS, GaleRP, et al. (2004). A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104:579–585.
10.
OranB, GiraltS, SalibaR, HosingC, PopatU, KhouriI, CourielD, QazilbashM, AnderliniP, et al. (2007). Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol BIood Marrow Transplant, 13:454–462.
11.
PrebetT, BoisselN, ReutenauerS, ThomasX, DelaunayJ, CahnJY, PigneuxA, QuesnelB, WitzF, et al. (2009). Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol, 27:4747–4753.
12.
FaragSS, ArcherKJ, MrozekK, RuppertAS, CarrollAJ, VardimanJW, PettenatiMJ, BaerMR, QumsiyehMB, et al. (2006). Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood, 108:63–73.
13.
ChesonBD, BennettJM, KopeckyKJ, BüchnerT, WillmanCL, EsteyEH, SchifferCA, DoehnerH, TallmanMS, et al. (2003). Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol, 21:4642–4649.
14.
MoXD, ZhangXH, XuLP, WangY, YanCH, ChenH, ChenYR, HanW, WangFR, et al. (2015). Salvage chemotherapy followed by granulocyte colonystimulating factor-primed donor leukocyte infusion with graft-vs-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol, 96:297–308.
15.
KarnofskyDA and BurchenalJ, eds. (1949). The Clinical Evaluation of Chemotherapeutic Agents in Cancer. Columbia University Press, New York.
16.
MorV, LaliberteL, MorrisJN and WiemannM. (1984). The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer, 53:2002–2007.
17.
HjermstadMJ, EvensenSA, KvalyS, FayersPM and KaasaS. (1998). Health-related quality of life 1 year after allogeneic or autologous stem cell transplantation: aprospective study. J Clin Oncol, 17:706–718.
18.
KaplanEL and MeierP. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53:457–481.
19.
CoxD. (1972). Regressionmodels and life tables. J R Stat Soc B, 34:187–220.
20.
MartinoR, IacobelliS, BrandR, JansenT, BiezenA, FinkeJ, BacigalupoA, BeelenD, ReiffersJ, et al. (2006). Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood, 108:836–846.
21.
IngramW, LimZY and MuftiGJ. (2007). Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev, 21:61–71.
22.
MarcondesM and DeegHJ. (2008). Hematopoietie cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?. Best Pract Res Clin Haematol, 2l:67–77.
23.
DeegHJ, StorerB, SlatteryJT, AnasettiC, DoneyKC, HansenJA, KiemHP, MartinPJ, PetersdorfE, et al. (2002). Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodys plastic syndrome. Blood, 100:1201–1207.
24.
de LimaM, AnagnostopoulosA, MunsellM, ShahjahanM, UenoN, IppolitiC, AnderssonBS, GajewskiJ, CourielD, et al. (2004). Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 104:865–872.
25.
de LimaM, CourielD, ThallPF, WangX, MaddenT, JonesR, ShpalEJ, ShahjahanM, PierreB, et al. (2004). Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104:857–864.
26.
HoAY, PagliucaA, KenyonM, ParkerJE, MijovicA, DevereuxS and MuftiGJ. (2004). Reduced-intensity allogeneic haematopoietic stem cell transplantation for Myelodysplastic syndrome and acute myeloid leukaemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 104:1616–1623.
27.
NakamuraR, RodriguezR, PalmerJ, SteinA, NaingA, TsaiN, ChangK, SlovakML, BhatiaR, et al. (2007). Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in Myelodysplastic syndrome. Bone Marrow Transplant, 40:843–850.
28.
MartinoR, CaballeroMD, SimonJA, CanalsC, SolanoC, Urbano-IspizuaA, BargayJ, LéonA, SarráJ, et al. (2002). Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 100:2243–2245.
29.
SmitsEL, AnguilleS and BernemanZN. (2013). Interferon-a may be back on track to treat acute myeloid leukemia. Oncoimmunology, 2:e23619.
30.
AnguilleS, LionE, WillemenY, Van TendelooVF, BernemanZN and SmitsEL. (2011). Interferon-a in acute myeloid leukemia: an old drug revisited. Leukemia, 25:739–748.
